

Otitis Media Treatment Pipeline Review H1 2016

Otitis Media - Pipeline Review, H2 2016

PUNE, INDIA, August 30, 2016
/EINPresswire.com/ -- Summary

'[Otitis Media](#) - Pipeline Review, H2 2016', provides an overview of the Otitis Media pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Otitis Media, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects.

Complete report details @ <https://www.wiseguyreports.com/reports/619242-otitis-media-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios,



enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/619242-otitis-media-pipeline-review-h2-2016>

Scope

- The report provides a snapshot of the global therapeutic landscape of Otitis Media
- The report reviews pipeline therapeutics for Otitis Media by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Otitis Media therapeutics and enlists all their major and minor projects
- The report assesses Otitis Media therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Otitis Media

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Otitis Media
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/619242-otitis-media-pipeline-review-h2-2016>

Key points in table of content	
Table of Contents	2
List of Tables	5
List of Figures	6
Introduction	7
Global Markets Direct Report Coverage	7
Otitis Media Overview	8
Therapeutics Development	9
Pipeline Products for Otitis Media - Overview	9
Pipeline Products for Otitis Media - Comparative Analysis	10
Otitis Media - Therapeutics under Development by Companies	11
Otitis Media - Therapeutics under Investigation by Universities/Institutes	12
Otitis Media - Pipeline Products Glance	13
Late Stage Products	13
Clinical Stage Products	14
Early Stage Products	15
Otitis Media - Products under Development by Companies	16
Otitis Media - Products under Investigation by Universities/Institutes	17
Otitis Media - Companies Involved in Therapeutics Development	18
Cellceutix Corporation	18
ContraFect Corporation	19
GlaxoSmithKline Plc	20
Lee's Pharmaceutical Holdings Limited	21
Madam Therapeutics B.V.	22
Merck & Co., Inc.	23
MerLion Pharmaceuticals Pte Ltd	24
Oticpharma Ltd	25
Otonomy, Inc.	26
Yuhan Corporation	27
Otitis Media - Therapeutics Assessment	28
Assessment by Monotherapy Products	28
Assessment by Combination Products	29
Assessment by Target	30
Assessment by Mechanism of Action	32
Assessment by Route of Administration	34
Assessment by Molecule Type	36
Drug Profiles	38
(dexamethasone acetate + piperacillin sodium + tazobactam sodium) - Drug Profile	38
Product Description	38
Mechanism Of Action	38
R&D Progress	38
betahistine dihydrochloride - Drug Profile	39
Product Description	39

Mechanism Of Action 39
R&D Progress 39
brilacidin tetrahydrochloride - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
CF-303 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
CF-309 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
ciprofloxacin hydrochloride - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
ciprofloxacin hydrochloride SR - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
finafloxacin - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
GSK-2189242A - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
pazufloxacin - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
PCL-1402 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections -
Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62

Small Molecules for Otitis Media - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619242

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/342360422>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.